Daratumumab (Anti-Cd38) Induces Loss Of Cd38 On Red Blood Cells

H. C. Sullivan, C. Gerner-Schmidt,L. Thompson, R. Jacob, C. Dean,M. Yee,R. Fasano,S. Lonial,R. M. Kaufman,S. R. Stowell

TRANSFUSION（2016）

引用 69|浏览20

暂无评分

摘要

To the editor:The recently approved anti-CD38 monoclonal antibody daratumumab (DARA) provides a unique therapeutic strategy that more selectively targets plasma cells in patients with plasma cell myeloma.[1][1][⇓][2][⇓][3][⇓][4][⇓][5]-[6][6] While DARA recognizes and removes malignant

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要